SRSF2 and acute myeloid leukemia: FLT3 (p = 0.019), TP53 (p = 0.020), MUC16 (p = 0.044), SRSF2 (p = 0.007), and KDM5A (p = 0.022) mutations were significantly more frequent in s‐AML (Table 7, Figure 8A).